Live Q&A: Real-world Tactics to Address Health Inequities in Lung Cancer CarePremiere Date: Tuesday, October 18, 2022
This activity will offer CE credit for:
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
- Dietetic Registration (CDR)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Wednesday, October 18, 2023
Note: Credit Is No Longer Available
|Edith Peterson Mitchell, MD, MACP, FCPP, FRCP (Moderator)
Clinical Professor of Medicine and Medical Oncology
Department of Medical Oncology
Director, Center to Eliminate Cancer Disparities
Associate Director, Diversity Affairs
Sidney Kimmel Cancer Center at Jefferson
116th President of the National Medical Association
|Ana I. Velázquez Mañana, MD, MSc
Assistant Professor, Division of Hematology Oncology
Zuckerberg San Francisco General Hospital
Assistant Director of Diversity, Equity, Inclusion and Accessibility
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA
Despite lung cancer being the leading cause of cancer mortality, its survival rate has continued to increase over the past 5 years. However, chasms in early diagnosis, treatment options and access, survival rate, and more remain for racial and ethnic underserved populations. A culmination of biases, disparities, and inequities continues a cycle of inadequate oncological treatment for lung cancer, thus resulting in delayed diagnosis, clinical management and treatment, prognosis, and survival rate.
This live Q&A session is your opportunity to ask questions based on the CME Outfitters BriefCase that focused on racial and ethnic disparities and health inequities in lung cancer.
At the end of this CE activity, participants should be able to:
- Recognize the impact of health inequities on patients with lung cancer and develop individual treatment strategies for optimal clinical outcomes.
Supported by an educational grant from the Johnson & Johnson Institute and the Johnson & Johnson Family of Companies.
Physicians, PAs, NPs, nurses/nurse navigators, pharmacists, and dietitians specializing in oncology, pathology, radiology, pulmonology, and primary care.
Specific CE Credit information is not available at this time. Please check again soon!It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Mitchell reports the following financial relationships:
Advisory Board: Corvus Pharmaceuticals, Inc.
Consultant: Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; Genentech, Inc.; and SEMA4 OpCo, Inc.
Dr. Velázquez Mañana reports the following financial relationships:
Stock Shareholder (directly purchased): Corbus Pharmaceuticals Holdings, Inc.
Other Financial or Material Support: LEAD Conference advisory committee member organized by BioAscend; Stipend from MDOutlook and Curio Science; and Travel Support from DAVA Oncology
The following peer reviewer and CME Outfitters staff have no financial relationships:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).